144043-17-4

Basic information

• Product Name: (3R)-(-)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE
• Synonyms: (3R)-(-)-Benzyl-3-(methylamino)pyrrolidine;(3R)-1-Benzyl-N-methyl-3-pyrrolidinamine;(3R)-(-)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE
• CAS NO: 144043-17-4
• Molecular Formula: C₁₂H₁₈N₂
• Molecular Weight: 190.28
• Product Categories: Amines and Anilines;Heterocycles;3-Aminopyrrolidines;Amines (Chiral);Chiral 3-Aminopyrrolidines;Chiral Building Blocks;Synthetic Organic Chemistry
• Mol File: 144043-17-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 273.066 °C at 760 mmHg
• Flash Point: 105.62 °C
• Appearance: /
• Density: 0,99 g/cm3
• Refractive Index: -3 ° (C=10, EtOH)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.16±0.20(Predicted)
• CAS DataBase Reference: (3R)-(-)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (3R)-(-)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE(144043-17-4)
• EPA Substance Registry System: (3R)-(-)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE(144043-17-4)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 144043-17-4(Hazardous Substances Data)

Usage

General Description

(3R)-(-)-1-Benzyl-3-(methylamino)pyrrolidine is a chiral compound with a pyrrolidine ring structure. It contains a benzyl group and a methylamino group attached to the pyrrolidine ring. (3R)-(-)-1-Benzyl-3-(methylamino)pyrrolidine is used in organic synthesis and pharmaceutical research due to its potential as a building block for creating biologically active molecules. It has been studied for its potential pharmacological properties and is known to exhibit specific stereochemistry, which can influence its interactions with biological targets. The compound’s chiral nature and unique structural features make it an important tool for drug development and chemical research.

Upstream product

• 131852-54-5 (3R)-(-)-1-benzyl-3-aminopyrrolidine hydrochloride 
• 116183-79-0 (3S)-3-<(4-tolylsulfonyl)oxy>-1-(phenylmethyl)pyrrolidine 
• 74-89-5 methylamine 
• 131878-23-4 (3R)-1-benzyl-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine 
• 114715-39-8 (R)-1-benzyl-3-aminopyrrolidine 
• 101385-90-4 (S)-N-benzyl-3-hydroxypyrrolidine 

Downstream Products

• 392338-15-7 tert-butyl [(3R)-pyrrolidin-3-yl]methylcarbamate 
• 1313412-63-3 (R)tert-butyl 1-(2-amino-6-(benzyloxymethyl)pyrimidin-4-yl)pyrroIidin-3yl(methyl)carbamate 
• 1163123-42-9 ((R)-1-benzyl-pyrrolidin-3-yl)-(6-chloro-benzooxazol-2-yl)-methyl-amine 
• 801252-82-4 tert-butyl (3R)-N-(1-benzyl-3-pyrrolidinyl)-N-methylcarbamate hydrochloride 

Relevant articles and documents

JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF

Janus kinase 1 selective inhibitors and pharmaceutical use thereof are provided.

Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor

A series of 3(R)-aminopyrrolidine derivatives were designed and synthesized for JAK1-selective inhibitors through the modification of tofacitinib's core structure, (3R,4R)-3-amino-4-methylpiperidine. From the new core structures, we selected (R)-N-methyl-N-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a scaffold for further SAR studies. From biochemical enzyme assays and liver microsomal stability tests, (R)-3-(3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile (6) was chosen for further in vivo test through oral administration. Compound 6 showed improved selectivity for JAK1 compared to that of tofacitinib (IC50 11, 2.4 × 102, 2.8 × 103, and 1.1 × 102 nM for JAK1, JAK2, JAK3, and TYK2, respectively). In CIA and AIA model tests, compound 6 exhibited similar efficacy to tofacitinib citrate.